Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Next Previous
Trial Profile

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Droxidopa (Primary)
  • Indications Orthostatic hypotension; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Chelsea Therapeutics

    • Most Recent Events

    • 20 May 2017 Results (n=120) assessing the imapct of droxidopa on fear of falling in patients with Parkinson disease and symptomatic nOH, presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society.
    • 06 Jan 2017 Results (n=907) assessing CV safety of Droxidopa using patient data from NOH-301, NOH-302, NOH-303, NOH-304 and NOH-306 trials published in the American Journal of Cardiology.
    • 12 Jun 2016 Results assessing comparison of the rate of patient-reported falls (n = 197) published in the Clinical Neuropharmacology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top